New pharmacological approaches to atrial fibrillation

Drug Discovery Today

Volumn 17, Issue 13-14, 2012, Pages 654-659

  Milnes, James T ^a   Madge, David J ^a   Ford, John W ^a  

^a Xention Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; AZD 2739; BMS 394136; BMS 914392; DRONEDARONE; INAKALANT; KVI 0201; LIDOCAINE; MEXILETINE; NIP 142; NIP 151; NTC 801; PLACEBO; RANOLAZINE; UNCLASSIFIED DRUG; VERNAKALANT; WYE 160020; XEN D 0101; XEN D 101; XEN D 103; XEN R 0702;

ANTICOAGULANT THERAPY; ECONOMIC ASPECT; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; PHYSICIAN; PREVALENCE; REVIEW; SINUS RHYTHM;

EID: 84863536580     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.02.007     Document Type: Short Survey

References (42)

1. European Medicines Agency recommends restricting use of Multaq. Benefit-risk balance of anti-arrhythmic medicine remains positive in a limited population of patients with paroxysmal or persistent atrial fibrillation. EMA/CHMP/718819/201122
2. v1.5 cloned channel currents Circ. Res. 73 1993 1061 1076 (Pubitemid 23340202)
3. + channel current Circ. Res. 73 1993 210 216 (Pubitemid 23173072)
4. G.J. Amos Differences between outward currents of human atrial and subepicardial ventricular myocytes J. Physiol. 491 1996 31 50 (Pubitemid 26059547)
5. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation Circulation 110 2004 2299 2306 (Pubitemid 39407330)
6. J. Feng Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences Am. J. Physiol. 275 1998 1717 1725
7. R. Caballero In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both J. Am. Coll. Cardiol. 55 2010 2346 2354
8. T.M. Olson Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation Hum. Mol. Genet. 15 2006 2185 2191 (Pubitemid 43985509)
9. 2+ model: sinus rhythm and chronic atrial fibrillation Circ. Res. 109 2011 1055 1066
10. J. Lloyd Pyrrolidine amides of pyrazolodihydro-pyrimidines as potent and selective Kv1.5 blockers Bioorg. Med. Chem. Lett. 20 2010 1436 1439
11. Kur blocker, BMS-394136 selectively prolongs atrial APD and refractoriness in beagles and rabbits Circulation 120 2009 S654
12. v1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl) -2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia J. Med. Chem. 52 2009 6531 6534
13. Kur) over other cardiac ion channels Circulation 118 2008 S342
14. v1.5 blocker in dogs Heart Rhythm 2 2005 S180
15. v1.5 blocker in dogs with atrial tachycardia remodeling Heart Rhythm 3 2006 P3 P17
16. v1.5 inhibitor with atrial fibrillation suppressing effects in the dog J. Cardiovasc. Electrophys. 22 2011 S170
17. + channel activity of neuronal and cardiac G-protein-activated inward rectifiers Biochem. Biophys. Res. Commun. 212 1995 657 663
18. +-channel proteins Nature 374 1995 135 141
19. P. Coumel Autonomic influences in atrial tachyarrhythmias J. Cardiovasc. Electrophysiol. 7 1996 999 1007 (Pubitemid 26337729)
20. K,ACh channels in patients with chronic atrial fibrillation Cardiovasc. Res. 74 2007 426 437 (Pubitemid 46693702)
21. (K,ACh) is constitutively active in patients with chronic atrial fibrillation Circulation 112 2005 3697 3706 (Pubitemid 43739509)
22. N. Voigt Left-to-right atrial inward-rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation Circ. Arrhythm. Electrophysiol. 3 2010 472 480
23. J.R. Ehrlich Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium J. Physiol. 557 2004 583 597 (Pubitemid 38807396)
24. H. Tanaka, and N. Hashimoto A multiple ion channel blocker, nip-142, for the treatment of atrial fibrillation Cardiovasc. Drug Rev. 25 2007 342 356 (Pubitemid 350237625)
25. Kr-blocker dofetilide J. Cardiovasc. Pharmacol. 51 2008 162 169 (Pubitemid 351301477)
26. + channel blocker on experimental atrial fibrillation Circ. Arrhythm. Electrophysiol. 4 2011 94 102
27. J.T. Milnes A selective inhibitor of human atrial ik,ach prolongs aerp in a tachypaced dog model of atrial fibrillation Heart Rhythm 2011 PO5-125
28. K. Wickman Abnormal heart rate regulation in GIRK4 knockout mice Neuron 20 1998 103 114 (Pubitemid 28078353)
29. N. Hashimoto Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation Pharmacol. Res. 54 2006 136 141 (Pubitemid 44038385)
30. D. Yang Expression of inwardly rectifying potassium channel subunits in native human retinal pigment epithelium Exp. Eye Res. 87 2008 176 183
31. K.W. Chan A recombinant inwardly rectifying potassium channel coupled to GTP-binding proteins J. Gen. Physiol. 107 1996 381 397
32. + channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension Science 331 2011 768 772
33. + channel FEBS Lett. 444 1999 265 269 (Pubitemid 29092815)
34. A. Burashnikov Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation Heart Rhythm 5 2008 1735 1742
35. R.N. Goldstein AZD7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model J. Cardiovasc. Electrophysiol. 15 2004 1444 1450 (Pubitemid 40013678)
36. G. Beatch Electrophysiological mechanism of RSD1235, a new atrial fibrillation converting drug Circulation 108 2003 85
37. A.E. Lacerda Vanoxerine: cellular mechanism of a new antiarrhythmic J. Cardiovasc. Electrophysiol. 21 2010 301 310
38. + channels by ranolazine: I. Experimental analysis of the use-dependent block Am. J. Physiol. Heart Circ. Physiol. 301 2011 1606 1614
39. A. Burashnikov Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine Circulation 116 2007 1449 1457 (Pubitemid 47480635)
40. B.M. Scirica Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial Circulation 116 2007 1647 1652 (Pubitemid 47537839)
41. R.H. Miles Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting Am. J. Cardiol. 108 2011 673 676
42. J. Bechard, and M.J. Pourrier Atrial selective effects of intravenously administered vernakalant in conscious beagle dogs Cardiovasc. Pharmacol. 58 2011 49 55